Login to Your Account

Deals And M&A NEWS

Eight years after Ionis Pharmaceuticals Inc. selected then-independent Genzyme Corp. as the partner for its phase III lipid-lowering drug, mipomersen, in a potential $1.9 billion deal, the Carlsbad, Calif.-based company dealt the commercial asset, Kynamro, to start-up Kastle Therapeutics LLC for peanuts.

SHANGHAI – An unlikely union has been forged between San Francisco-based Unity Biotechnology Inc. and Ascentage Pharma Group, of Taizhou, Zhejiang.

Aytu Bioscience Inc. CEO Josh Disbrow said that confusion over what endpoints might be acceptable to the FDA in trials with therapies for low testosterone "is a bit of an anomaly, and frankly we view it to some degree as a barrier to entry that's relatively unique."

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: